Chester County News and Community Website
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has released its financial results for the first quarter of 2025, alongside significant updates on its pipeline advancements, including the upcoming Biologics License …
INOVIO Reports Q1 2025 Results and Key Developments in DNA Medicines Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced its participation in a series of high-profile conferences in May, where it will showcase pivotal data on its lead DNA immunotherapy …
INOVIO to Present Key Clinical Data at Major Scientific Conferences Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) will release its Q1 2025 financial results after market close on May 13, 2025. A live conference call and webcast will follow at …
INOVIO to Announce Q1 2025 Results and Host Live Webcast on May 13 Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced its participation in several prominent conferences, where it will present significant findings related to its lead candidate, INO-3107. The presentations will …
INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) released its financial results and operational highlights for 2024, marking significant strides in its pipeline and the broader development of DNA medicines.
INOVIO Reports Progress on INO-3107 and DNA Medicine, 2024 Financial Outcomes Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal antibodies (DMAbs) for COVID-19. Impressively, 100% of participants who reached …
INOVIO Reports Groundbreaking Results in COVID-19 Antibody Trial Read More PLYMOUTH MEETING, PA —INOVIO (NASDAQ: INO) has announced that it will release its fourth-quarter and year-end 2024 financial results on March 18, 2025, after the market closes. The company will …
INOVIO to Announce Q4 and Year-End 2024 Results on March 18, 2025 Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has unveiled promising peer-reviewed results from its Phase 1/2 clinical trial for INO-3107, a cutting-edge DNA medicine designed to treat recurrent respiratory papillomatosis (RRP). …
INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced that new research on its investigational immunotherapy, INO-3107, will be presented at the American Association for Cancer Research – Immuno-Oncology conference from …
INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Dr. Jacqueline Shea, the company’s President and CEO, along with Dr. …
INOVIO to Present at Oppenheimer Healthcare Life Sciences Conference Read More